People who experience their first-ever bout of depression after having a heart attack are at greater risk for future heart problems than are patients who either don’t become clinically depressed after the medical emergency or who were depressed even before the incident, new research shows.
As a result, new depression-related screening protocols and treatment strategies may be needed to help reduce the likelihood of future heart problems in these patients, according to the research, which appears in the Dec. 5, 2006 edition of the Journal of the American College of Cardiology.
Known as the DepreMI Study, the research was conducted in the Netherlands at University Medical Centre Groningen, part of the University of Groningen. Lead researcher Peter de Jonge, PhD, said the team was seeking to determine whether all types of depression could be considered a direct cause of heart attack. What the group found was a bit surprising.
“We found that only incident (first-time) depression – no other type – was related to a poor prognosis,” said Dr. de Jonge, an assistant professor of internal medicine and psychiatry at the University of Groningen. “In other words, our findings suggest that patients who experience depression after a heart attack, but never before, are at particular risk for future incidents.
“Based on other studies, it appears that standard antidepressive treatment may not be sufficient for this category of patients,” Dr. de Jonge continued. “We feel that especially in these cases, antidepressive treatment should be integrated into cardiac after-care and made a prominent part of the rehabilitation program.”
Standard antidepressive treatment, which frequently includes medications to affect mood, may be insufficient, Dr. de Jonge explained, because incident post-heart attack depression is different than typical depression.
Patients with post-heart attack depression often have survived more severe medical emergencies than other heart attack patients, he said. As a result, these patients may be physically more exhausted and vulnerable than their peers.
“[T]his finding may explain the relatively high effectiveness of psychoeducational interventions, including stress management and relaxation, to prevent cardiac events in coronary artery disease patients,” the researchers state in their manuscript.
For the study, the researchers observed 468 patients hospitalized for heart attack for a mean follow-up period of 2.5 years. Patients were clinically evaluated for depression while in the hospital and again at three months and 12 months post-heart attack. Those with heart attack-related depression experienced more fatal and non-fatal cardiovascular emergencies than did patients who either did not become depressed or who were depressed before having a heart attack.
Based on these findings, Dr. de Jonge said, researchers need to create interventional studies in which non-standard treatments for depression are evaluated in patients with post-heart attack depression to determine which methods are most effective in protecting long-term health.
Roland von Känel, MD, a professor of medicine and head of the psychosomatic division at University Hospital Berne in Switzerland, did not participate in the study, but said it provides important information on “cardiotoxic” subtypes of depression and clues on improving care. Dr. von Känel is the first author of an editorial comment about heart attack and depression that will be published in conjunction with the new research.
“Given what we now know, I believe that screening for depression should be part of today’s clinical practice in a cardiology setting any time a patient is referred to the ICU with a heart attack,” Dr. von Känel said. “Depressed patients should be treated with counseling, referral to a psychotherapist and/or antidepressant medication – preferably an SSRI (selective serotonin reuptake inhibitor) – depending upon the severity of their depression.”
SSRI medications seek to improve mood by slowing the reuptake of the neurotransmitter serotonin in the brain; the medications have been shown to be safe and efficient in patients with heart disease. Serotonin affects emotions, mood and thought.
“In addition, improving social support, establishing a physical exercise regimen and addressing psychosocial issues, such as job situation, family conflicts and stress-causing health concerns, also may be necessary,” Dr. von Känel said. “All of these things will work together to benefit quality of life, improve adherence to cardiac treatment and reduce health care costs.”
The next steps, Dr. von Känel said, are to conduct additional research to ensure that patients receive the most effective treatments and to determine which of these treatments improve hard cardiovascular end-points, such as recurrent heart attack.
“There is no study showing to date that treatment of depression with psychotherapy improves cardiac or overall survival,” he said. “Non-randomized studies show, however, that SSRIs may benefit depressed patients after a heart attack in terms of improving cardiovascular outcome. A randomized double-blind, placebo-controlled trial with an antidepressant as well as an individually tailored psychotherapeutic intervention study are badly needed to resolve these issues.”
Amy Murphy | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences